RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  R. Smits,et al.  The Functional Landscape of Patient-Derived RNF43 Mutations Predicts Sensitivity to Wnt Inhibition , 2020, Cancer Research.

[3]  R. Lindeboom,et al.  RNF43 truncations trap CK1 to drive niche‐independent self‐renewal in cancer , 2020, The EMBO journal.

[4]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[5]  R. Jamal,et al.  Actionable Potentials of Less Frequently Mutated Genes in Colorectal Cancer and Their Roles in Precision Medicine , 2020, Biomolecules.

[6]  R. Smits,et al.  Commonly observed RNF43 mutations retain functionality in attenuating Wnt/β-catenin signaling and unlikely confer Wnt-dependency onto colorectal cancers , 2020, Oncogene.

[7]  Angela N. Brooks,et al.  eVIP2: Expression-based variant impact phenotyping to predict the function of gene variants , 2019, bioRxiv.

[8]  G. Lesinski,et al.  Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms , 2019, British Journal of Cancer.

[9]  Soohyung Park,et al.  The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis , 2019, Scientific Reports.

[10]  Jun Yu,et al.  Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity , 2019, Nature Microbiology.

[11]  Haifeng Liu,et al.  FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells , 2018, Nature.

[12]  Wei Yang,et al.  FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells , 2018, Nature.

[13]  W. Cheung,et al.  Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy , 2018, Canadian journal of gastroenterology & hepatology.

[14]  Bon-Kyoung Koo,et al.  Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis , 2018, Cell.

[15]  Ritika Kundra,et al.  Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. , 2018, Cancer cell.

[16]  Kentaro Inamura,et al.  Colorectal Cancers: An Update on Their Molecular Pathology , 2018, Cancers.

[17]  Jing Wang,et al.  The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. , 2017, Cell chemical biology.

[18]  Philip S Rosenberg,et al.  Colorectal Cancer Incidence Patterns in the United States, 1974–2013 , 2017, Journal of the National Cancer Institute.

[19]  L. Cantley,et al.  PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α , 2017, Proceedings of the National Academy of Sciences.

[20]  Lovelace J. Luquette,et al.  A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. , 2017, Cancer cell.

[21]  Jacob K. Asiedu,et al.  The Drug Repurposing Hub: a next-generation drug library and information resource , 2017, Nature Medicine.

[22]  Yiling Lu,et al.  Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. , 2017, Cancer cell.

[23]  H. Clevers,et al.  RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation , 2016, Gut.

[24]  S. Gabriel,et al.  Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma , 2016, Cell reports.

[25]  H. Clevers,et al.  Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3-mutant neoplasia , 2015, Proceedings of the National Academy of Sciences.

[26]  Hayley E. Francies,et al.  Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients , 2015, Cell.

[27]  Yang Zhang,et al.  I-TASSER server: new development for protein structure and function predictions , 2015, Nucleic Acids Res..

[28]  Jean J. Zhao,et al.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting , 2014, Nature Reviews Cancer.

[29]  Kristian Cibulskis,et al.  RNF43 is frequently mutated in colorectal and endometrial cancers , 2014, Nature Genetics.

[30]  Liam O'Connor,et al.  Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. , 2014, Cancer research.

[31]  Prahlad T. Ram,et al.  A pan-cancer proteomic perspective on The Cancer Genome Atlas , 2014, Nature Communications.

[32]  Feng Cong,et al.  Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma , 2013, Proceedings of the National Academy of Sciences.

[33]  Jeffrey J Meyer,et al.  Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. (5) , 2013 .

[34]  Y. Liu,et al.  Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells , 2013, Proceedings of the National Academy of Sciences.

[35]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[36]  H. Clevers,et al.  Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors , 2012, Nature.

[37]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[38]  H. Ruffner,et al.  ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner , 2012, Nature.

[39]  G. Mills,et al.  High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. , 2011, Cancer discovery.

[40]  Yang Zhang,et al.  I-TASSER: a unified platform for automated protein structure and function prediction , 2010, Nature Protocols.

[41]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[42]  L. Cantley,et al.  Then Negative Regulation of Phosphoinositide 3-Kinase Signaling by p85 and Its Implication in Cancer , 2005 .

[43]  L. Cantley,et al.  The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer. , 2005, Cell cycle.

[44]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.